POLO: A randomized phase III trial of olaparib maintenance monotherapy in patients (pts) with metastatic pancreatic cancer (mPC) who have a germline BRCA1/2 mutation (gBRCAm).

被引：6

作者：

Golan, Talia

Oh, Do-Youn

Reni, Michele

Macarulla, Teresa Mercade

Tortora, Giampaolo

Hall, Michael J.

Reinacher-Schick, Anke C.

Borg, Christophe

Hochhauser, Daniel

Walter, Thomas

Hochster, Howard S.

Baker, Nigel

Locker, Gershon Y.

Kindler, Hedy L.

机构：

[1] Sheba Med Ctr, Oncol Inst, Tel Hashomer, Israel

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Hosp San Raffaele, Milan, Italy

[4] Vall Hebron Univ Hosp HUVH, Barcelona, Spain

[5] Vall Hebron Inst Oncol VHIO, Barcelona, Spain

[6] Med Sch, Verona, Italy

[7] Univ Hosp, Verona, Italy

[8] Fox Chase Canc Ctr, Philadelphia, PA USA

[9] Klinikum Ruhr Univ Bochum, St Josef Hosp, Bochum, Germany

[10] Hop Jean Minjoz, Besancon, France

[11] UCL, UCL Canc Inst, London, England

[12] Hop Edouard Herriot, Lyon, France

[13] Yale New Haven Med Ctr, 20 York St, New Haven, CT 06504 USA

[14] AstraZeneca, Cambridge, England

[15] AstraZeneca, Gaithersburg, MD USA

[16] Univ Chicago, Chicago, IL 60637 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.TPS4152

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS4152

引用

页数：2

共 50 条

[41] POLO: Long-term safety and tolerability of olaparib for patients with a germline BRCA mutation and metastatic pancreatic cancer
Arnold, D.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Mercade, T. Macarulla
Hall, M. J.
Park, J. O.
Hochhauser, D.
Oh, D-Y.
Reinacher-Schick, A.
Tortora, G.
Algul, H.
O'Reilly, E. M.
Bordia, S.
McGuinness, D.
Cui, K. Y.
Locker, G.
Kindler, H.
ANNALS OF ONCOLOGY, 2021, 32 : S1085 - S1086
[42] Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
Poveda Velasco, A. M.
Lheureux, S.
Colombo, N.
Cibula, D.
Elstrand, M.
Weberpals, J.
Bjurberg, M.
Oaknin, A.
Sikorska, M.
Gonzalez Martin, A. J.
Madry, R.
Rubio Perez, M. J.
Ledermann, J. A.
Ozgoren, O.
Barnicle, A.
Marshall, H.
Bashir, Z.
Skof, E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S790 - S790
[43] Geographic and Ethnic Heterogeneity of Germline BRCA1 or BRCA2 Mutation Prevalence Among Patients With Metastatic Pancreatic Cancer Screened for Entry Into the POLO Trial
Golan, Talia
Kindler, Hedy L.
Park, Joon Oh
Reni, Michele
Macarulla, Teresa
Hammel, Pascal
Van Cutsem, Eric
Arnold, Dirk
Hochhauser, Daniel
McGuinness, David
Locker, Gershon Y.
Goranova, Teodora
Schatz, Philipp
Liu, Yu-Zhen
Hall, Michael J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (13) : 1442 - +
[44] Extended Overall Survival Results from the POLO Study of active Maintenance Therapy with Olaparib in Patients with metastatic Pancreatic Cancer and a Germline BRCA Mutation
Arnold, D.
Golan, T.
Hammel, P.
Reni, M.
Van Cutsem, E.
Macarulla, T.
Hall, J. M.
Park, Oh J.
Hochhauser, D.
Oh, D. -Y.
Reinacher-Schick, A.
Tortora, G.
Alguel, H.
O'Reilly, M. E.
Kindler, L. H.
Sharan, K.
Ou, X.
Cui, K.
Locker, Y. G.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 224 - 225
[45] Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Macarulla, Teresa
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Arnold, Dirk
Oh, Do-Youn
Reinacher-Schick, Anke
Tortora, Giampaolo
Alguel, Hana
O'Reilly, Eileen M.
Bordia, Sonal
McGuinness, David
Cui, Karen
Locker, Gershon Y.
Golan, Talia
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (34) : 3929 - +
[46] Randomized phase II trial of olaparib plus pembrolizumab versus olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) mutations: SWOG S2001
Chung, Vincent
Guthrie, Katherine A.
Pishvaian, Michael J.
Lowy, Andrew M.
Chiorean, Elena Gabriela
Duong, Mai T.
O'Reilly, Eileen Mary
Philip, Philip Agop
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[47] Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
Im, Seock-Ah
Xu, Binghe
Li, Wei
Robson, Mark
Ouyang, Quchang
Yeh, Dah-Cherng
Iwata, Hiroji
Park, Yeon Hee
Sohn, Joo Hyuk
Tseng, Ling-Ming
Goessl, Carsten
Wu, Wenting
Masuda, Norikazu
SCIENTIFIC REPORTS, 2020, 10 (01)
[48] Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
Seock-Ah Im
Binghe Xu
Wei Li
Mark Robson
Quchang Ouyang
Dah-Cherng Yeh
Hiroji Iwata
Yeon Hee Park
Joo Hyuk Sohn
Ling-Ming Tseng
Carsten Goessl
Wenting Wu
Norikazu Masuda
Scientific Reports, 10
[49] Randomized phase II trial of olaparib plus pembrolizumab vs olaparib alone as maintenance therapy in metastatic pancreatic cancer patients with germline BRCA1 or BRCA2 (gBRCA1/2+) pathogenic variants: SWOG S2001.
Chung, Vincent
Guthrie, Katherine A.
Pishvaian, Michael J.
Reiss, Kim Anna
Lowy, Andrew M.
Sohal, Davendra
Colby, Sarah
Sharon, Elad
Allegra, Carmen Joseph
O'Reilly, Eileen Mary
Chiorean, E. Gabriela
Philip, Philip Agop
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] POLO: Efficacy and Health-Related Quality of Life (HRQOL) with Maintenance Olaparib Following First-Line Platinum-Based Chemotherapy (PBC) in Patients (PTS) with a Germline BRCA Mutation and Metastatic Pancreatic Cancer (MPC)
Reinacher-Schick, Anke C.
Kindler, Hedy L.
Hammel, Pascal
Reni, Michele
Van Cutsem, Eric
Mercade, Teresa Macarulla
Hall, Michael J.
Park, Joon Oh
Hochhauser, Daniel
Oh, Do-Youn
Tortora, Giampaolo
Algul, Hana
O'reilly, Eileen M.
Mcguinness, David
Cui, Karen
Schlienger, Katia
Locker, Gershon Y.
Golan, Talia
Arnold, Dirk
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 68 - 68

← 1 2 3 4 5 →